Liraglutide

About Liraglutide

Liraglutide is a synthetic analogue of human glucagon-like peptide-1 (GLP-1) used in laboratory research. It is studied for its molecular mechanisms and receptor binding properties.

This research peptide is supplied as a lyophilized powder that requires reconstitution before use in laboratory applications. It is provided at research-grade purity for in-vitro studies only.

Research Applications: Liraglutide is used exclusively for laboratory research purposes. It is not intended for human consumption, medical treatment, or any form of in-vivo application.

Storage: Store lyophilized powder at -20°C. After reconstitution, store at 2-8°C and use within the timeframe specified by the manufacturer.

Detailed Research Information

Liraglutide is a synthetic acylated GLP-1 receptor agonist peptide used extensively in metabolic research laboratories. As a research compound, Liraglutide is studied for its interactions with incretin hormone pathways, glucose homeostasis mechanisms, and appetite regulation systems.

Key Research Applications

Incretin Pathway Research: Liraglutide is utilized in studies investigating GLP-1 receptor activation and its downstream effects on glucose-dependent insulin secretion, glucagon suppression, and pancreatic beta-cell function.

Metabolic Studies: Research applications include examination of gastric emptying mechanisms, central nervous system appetite regulation pathways, and energy expenditure dynamics in laboratory models.

Cardiovascular Metabolism: Liraglutide is employed in research exploring metabolic-cardiovascular interactions, lipid metabolism pathways, and vascular endothelial function in experimental settings.

Neuropeptide Research: Studies utilize Liraglutide to investigate central GLP-1 receptor distribution, hypothalamic signaling cascades, and neurometabolic regulatory mechanisms.

Mechanism of Action

Liraglutide functions through selective activation of GLP-1 receptors, which are coupled to G-protein signaling cascades. The acylation modification extends the peptide's half-life by promoting albumin binding and reducing renal clearance. Research demonstrates that Liraglutide activates adenylyl cyclase pathways, increasing intracellular cAMP concentrations and modulating calcium channel activity in pancreatic beta-cells, leading to glucose-dependent insulin secretion enhancement.

Product Specifications

All listed research peptides are supplied in lyophilized (freeze-dried) powder form and require reconstitution with bacteriostatic water or sterile water before use in laboratory applications. Products are intended exclusively for in vitro research and are not for human consumption.